NIPH Clinical Trials Search

An Observational Study Evaluating Clinicopathological Features of Patients with FGFR2b Positive Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma(WJOG18524GPS)

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	FGFR2b positive unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma
Date of first enrollment	2025/03/03
Target sample size	1000
Countries of recruitment	Japan
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	the proportion of FGFR2b-positive cases of unresectable advanced or recurrent gastric cancer
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	18years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1) Active double cancer requiring active treatment such as chemotherapy or surgery (synchronous or metachronous double cancer with a disease-free period of 3 years). Exceptions include cases where the risk of metastasis or death is negligible and cure is expected with local treatment (e.g., appropriately treated cervical intraepithelial neoplasia, basal cell carcinoma, cutaneous squamous cell carcinoma, localized prostate cancer treated with curative intent, ductal carcinoma treated in situ with curative intent). 2) History of taxane-based agent administration (including neoadjuvant or adjuvant chemotherapy). 3) History of FGF-FGFR pathway or VEGF-VEGFR pathway inhibitor administration. 4) Cases deemed inappropriate for enrollment by the attending physician.